Literature DB >> 27535218

Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma.

F Linke1, M Harenberg1, M M Nietert2, S Zaunig1, F von Bonin1, A Arlt1, M Szczepanowski3, H A Weich4, S Lutz5, C Dullin6, P Janovská7, M Krafčíková8, L Trantírek8, P Ovesná9, W Klapper3, T Beissbarth2, F Alves1,6,10, V Bryja7,11, L Trümper1, J Wilting12, D Kube1.   

Abstract

The interaction between vascular endothelial cells (ECs) and cancer cells is of vital importance to understand tumor dissemination. A paradigmatic cancer to study cell-cell interactions is classical Hodgkin Lymphoma (cHL) owing to its complex microenvironment. The role of the interplay between cHL and ECs remains poorly understood. Here we identify canonical WNT pathway activity as important for the mutual interactions between cHL cells and ECs. We demonstrate that local canonical WNT signaling activates cHL cell chemotaxis toward ECs, adhesion to EC layers and cell invasion using not only the Wnt-inhibitor Dickkopf, tankyrases and casein kinase 1 inhibitors but also knockdown of the lymphocyte enhancer binding-factor 1 (LEF-1) and β-catenin in cHL cells. Furthermore, LEF-1- and β-catenin-regulated cHL secretome promoted EC migration, sprouting and vascular tube formation involving vascular endothelial growth factor A (VEGF-A). Importantly, high VEGFA expression is associated with a worse overall survival of cHL patients. These findings strongly support the concept that WNTs might function as a regulator of lymphoma dissemination by affecting cHL cell chemotaxis and promoting EC behavior and thus angiogenesis through paracrine interactions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27535218     DOI: 10.1038/leu.2016.232

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  51 in total

1.  Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.

Authors:  M Vockerodt; H Tesch; D Kube
Journal:  Genes Immun       Date:  2001-12       Impact factor: 2.676

2.  New Wnt/β-catenin target genes promote experimental metastasis and migration of colorectal cancer cells through different signals.

Authors:  Jingjing Qi; Yong Yu; Özlem Akilli Öztürk; Jane D Holland; Daniel Besser; Johannes Fritzmann; Annika Wulf-Goldenberg; Klaus Eckert; Iduna Fichtner; Walter Birchmeier
Journal:  Gut       Date:  2015-07-08       Impact factor: 23.059

3.  LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.

Authors:  Albert Gutierrez; Renee C Tschumper; Xiaosheng Wu; Tait D Shanafelt; Jeanette Eckel-Passow; Paul M Huddleston; Susan L Slager; Neil E Kay; Diane F Jelinek
Journal:  Blood       Date:  2010-07-01       Impact factor: 22.113

4.  Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib.

Authors:  H Mizuno; T Nakayama; Y Miyata; S Saito; S Nishiwaki; N Nakao; K Takeshita; T Naoe
Journal:  Leukemia       Date:  2012-03-20       Impact factor: 11.528

5.  STAT3 is constitutively activated in Hodgkin cell lines.

Authors:  D Kube; U Holtick; M Vockerodt; T Ahmadi; B Haier; I Behrmann; P C Heinrich; V Diehl; H Tesch
Journal:  Blood       Date:  2001-08-01       Impact factor: 22.113

6.  The NADPH oxidase inhibitor imipramine-blue in the treatment of Burkitt lymphoma.

Authors:  Marcel Klingenberg; Jürgen Becker; Sonja Eberth; Dieter Kube; Jörg Wilting
Journal:  Mol Cancer Ther       Date:  2014-01-30       Impact factor: 6.261

7.  Role of vascular endothelial growth factor C in classical Hodgkin lymphoma.

Authors:  Antonio Rueda; David Olmos; Luis Vicioso; Cristina Quero; Elena Gallego; Bella Isabel Pajares-Hachero; Marta Mendiola; María Casanova; Martina Álvarez; Mariano Provencio; Emilio Alba
Journal:  Leuk Lymphoma       Date:  2015-02-07

8.  Adhesion to high endothelial venules: a model for dissemination mechanisms in non-Hodgkin's lymphoma.

Authors:  R Stauder; S Hamader; B Fasching; G Kemmler; J Thaler; H Huber
Journal:  Blood       Date:  1993-07-01       Impact factor: 22.113

Review 9.  The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component.

Authors:  Yuxuan Liu; Ahmad Sattarzadeh; Arjan Diepstra; Lydia Visser; Anke van den Berg
Journal:  Semin Cancer Biol       Date:  2013-07-15       Impact factor: 15.707

10.  Crosstalk between VEGF and MTA1 signaling pathways contribute to aggressiveness of breast carcinoma.

Authors:  Sachin Raj M Nagaraj; Puttananjaiah Shilpa; Kavitha Rachaiah; Bharathi P Salimath
Journal:  Mol Carcinog       Date:  2013-11-22       Impact factor: 4.784

View more
  14 in total

Review 1.  Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.

Authors:  Pavlína Janovská; Vítězslav Bryja
Journal:  Br J Pharmacol       Date:  2017-08-30       Impact factor: 8.739

2.  Canonical and non-canonical Wnt signal pathway in classic Hodgkin lymphoma and the prognostic significance of LEF1, β-catenin, FZD6 and Wnt5a/b.

Authors:  Linlin Gao; Wei Cui; Sarah Kelting; Janet Woodroof; Hua Li; Linheng Li; Da Zhang
Journal:  Am J Blood Res       Date:  2022-08-15

3.  Oxymatrine enhanced anti-tumor effects of Bevacizumab against triple-negative breast cancer via abating Wnt/β-Catenin signaling pathway.

Authors:  Wei Xie; Yan Zhang; Shiwei Zhang; Fengxian Wang; Kunchi Zhang; Yanjuan Huang; Zhaoli Zhou; Gang Huang; Jin Wang
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

4.  WNT974 Inhibits Proliferation, Induces Apoptosis, and Enhances Chemosensitivity to Doxorubicin in Lymphoma Cells by Inhibiting Wnt/β-Catenin Signaling.

Authors:  Senmin Chen; Xiuli Yuan; Huanli Xu; Meng Yi; Sixi Liu; Feiqiu Wen
Journal:  Med Sci Monit       Date:  2020-06-29

5.  A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway.

Authors:  Wei Xie; Huijie Zhao; Fengxian Wang; Yiyun Wang; Yuan He; Tong Wang; Kunchi Zhang; Hao Yang; Zhaoli Zhou; Haibin Shi; Jin Wang; Gang Huang
Journal:  J Exp Clin Cancer Res       Date:  2021-01-12

Review 6.  Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth.

Authors:  Lutz Menzel; Uta E Höpken; Armin Rehm
Journal:  Front Immunol       Date:  2020-12-03       Impact factor: 7.561

7.  Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma.

Authors:  Weiwei Tao; Chengwei Chu; Wenchao Zhou; Zhi Huang; Kui Zhai; Xiaoguang Fang; Qian Huang; Aili Zhang; Xiuxing Wang; Xingjiang Yu; Haidong Huang; Qiulian Wu; Andrew E Sloan; Jennifer S Yu; Xiaoxia Li; George R Stark; Jeremy N Rich; Shideng Bao
Journal:  Nat Commun       Date:  2020-06-15       Impact factor: 14.919

8.  CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.

Authors:  Naike Casagrande; Cinzia Borghese; Lydia Visser; Maurizio Mongiat; Alfonso Colombatti; Donatella Aldinucci
Journal:  Haematologica       Date:  2018-10-11       Impact factor: 9.941

Review 9.  Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.

Authors:  Valli De Re; Laura Caggiari; Ombretta Repetto; Lara Mussolin; Maurizio Mascarin
Journal:  J Clin Med       Date:  2019-10-02       Impact factor: 4.241

Review 10.  Wnt Signaling in Leukemia and Its Bone Marrow Microenvironment.

Authors:  Yongsheng Ruan; Hye Na Kim; Heather Ogana; Yong-Mi Kim
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.